Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review

Bibliography

• Falkai P, Wobrock T, Lieberman J, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-91
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5-40
   PubMed Web of Science ®Google Scholar
• Tandon R, Belmaker RH, Gattaz WF, World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Thompson A, Carmody T, Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 2007;58:844-7
   PubMed Web of Science ®Google Scholar
• Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007;68:818-25
   PubMed Web of Science ®Google Scholar
• Rosa MA, Marcolin MA, Elkis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatr 2005;27:178-84
   PubMed Web of Science ®Google Scholar
• Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008;161:235-47
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust NZ J Psychiatry 2008;42:82-8
   Google Scholar
• Acosta FJ, Bosch E, Sarmiento G, Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 2009;107:213-17
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006;67:1114-23
   PubMed Web of Science ®Google Scholar
• McCann TV, Boardman G, Clark E, Lu S. Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs 2008;15:622-29
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Weiden PJ, Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-13
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8
   PubMed Web of Science ®Google Scholar
• Glazer WM, Byerly MJ. Tactics and technologies to manage nonadherence in patients with schizophrenia. Curr Psychiatry Rep 2008;10:359-69
   PubMedGoogle Scholar
• Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):9-14
   PubMed Web of Science ®Google Scholar
• Patel MX, de Zoysa N, Bernadt M, David AS. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral. J Clin Psychiatry 2008;69:1548-56
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7
   PubMed Web of Science ®Google Scholar
• Curson DA, Barnes TR, Bamber RW, Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 1985;146:469-74
   PubMedGoogle Scholar
• Heyscue BE, Levin GM, Merrick JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998;49:1232-4
   PubMed Web of Science ®Google Scholar
• Tunnicliffe S, Harrison G, Standen PJ. Factors affecting compliance with depot injection treatment in the community. Soc Psychiatry Psychiatr Epidemiol 1992;27:230-3
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008;30:2378-86
   PubMed Web of Science ®Google Scholar
• Kim B, Lee SH, Choi TK, Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1231-5
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(Suppl 16):14-17
   PubMedGoogle Scholar
• Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006;67:1948-53
   PubMed Web of Science ®Google Scholar
• Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22:275-82
   PubMed Web of Science ®Google Scholar
• Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009;23:789-96
   PubMed Web of Science ®Google Scholar
• Martinez G, Schreiner A. Risperidone long-acting injectable and olanzapine pamoate: review of short- and long-term safety data. Presented at the 9th World Federation of Societies of Biological Psychiatry; 29 June – 2 July 2009; Paris, France
   Google Scholar
• Moller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007;67:1541-66
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32
   PubMed Web of Science ®Google Scholar
• Lindenmayer J, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-9
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-17
   PubMed Web of Science ®Google Scholar
• Moller HJ. Long-acting risperidone: focus on safety. Clin Ther 2006;28:633-51
   PubMed Web of Science ®Google Scholar
• Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241-9
   PubMed Web of Science ®Google Scholar
• Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomized, controlled, open-label study. Br J Psychiatry 2007;191:131-9
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Wu B, A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006;39:135-41
   PubMed Web of Science ®Google Scholar
• Gastpar M, Masiak M, Latif MA, Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005;19(Suppl):32-8
   PubMedGoogle Scholar
• Mohl A, Westlye K, Opjordsmoen S, Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005;19(Suppl):22-31
   PubMedGoogle Scholar
• Moller HJ, Llorca PM, Sacchetti E, Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotics. Int Clin Psychopharmacol 2005;20:121-30
   PubMed Web of Science ®Google Scholar
• Parellada E, Andrezina R, Milanova V, Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005;19(Suppl):5-14
   PubMedGoogle Scholar
• Kissling W, Glue P, Medori R, Simpson S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 2007;22:505-13
   PubMed Web of Science ®Google Scholar
• Curtis VA, Katsafouros K, Moller H, Long-acting risperidone improves negative symptoms in stable psychotic patients. J Psychopharmaol 2008;22:254-61
   Web of Science ®Google Scholar
• Parellada E, Kouniakis F, Siurkute A, Survey of safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, non-interventional prospective study [abstract]. Eur Psychiatry 2009;24(Suppl 1):S1025
   Google Scholar
• Rosa F, Schreiner A, Thomas P, Sherif T. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Presented at European Meeting of Psychiatry; 24 – 28 January 2009; Lisbon, Portugal
   Google Scholar
• Rabinowitz J, Napryeyenko O, Burba O, Efficacy and tolerability among patients with recent onset schizophrenia treated with long - acting injectable risperidone – PROPEL study. Presented at 9th World Congress of Biological Psychiatry; 28 June – July 2 2009; Paris, France
   Google Scholar
• Bai YM, Ting Chen T, Chen JY, Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007;68:1218-25
   PubMed Web of Science ®Google Scholar
• Lee MS, Ko YH, Lee SH, Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006;21:399-407
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005;8:427-38
   PubMed Web of Science ®Google Scholar
• Kissling W, Heres S, Lloyd K, Direct transition to long-acting risperidone – analysis of long-term efficacy. J Psychopharmacol 2005;19(Suppl 1):15-21
   PubMedGoogle Scholar
• Simpson GM, Mahmoud RA, Lasser RA, A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006;67:1194-203
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Gearhart NC, Lasser RA, Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 2007;6:3
   PubMedGoogle Scholar
• Peuskens J, Van der Veken J, Diels J, Povey M. Improvements in illness severity, functioning and hospitalization in schizophrenic patients switched to risperidone long-acting injection (RLAI): 12-month interim report from Belgian patients enrolled in the electronic schizophrenia treatment adherence registry (e-STAR). Poster presented at the American Psychiatric Association Annual Meeting; 19 – 24 May 2007; San Diego, USA
   Google Scholar
• Garcia D, Duval F, Lopera FG, Weight gain and hyperprolactinemia in schizophrenic patients treated during twelve months with long acting risperidone [abstract]. Eur Psychiatry 2009;24(Suppl 1):S1004
   Google Scholar
• Lindenmayer J, Khan A, Eerdekens M, Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17:138-44
   PubMed Web of Science ®Google Scholar
• Llorca PM, Sacchetti E, Lloyd K, Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 2008;46:14-22
   PubMed Web of Science ®Google Scholar
• Emsley R, Medori R, Koen L, Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210-13
   PubMed Web of Science ®Google Scholar
• Gaebel W, Bergmans P, de Arce R, Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapine: Randomized, long-term, open-label, clinical trial results (ConstaTRE) [abstract]. Eur Psychiatry 2009;24(Suppl 1):S1020
   Google Scholar
• Taylor DM, Fischetti C, Sparshatt A, Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2009;70:196-200
   PubMed Web of Science ®Google Scholar
• Olivares JM, Peuskens J, Pecenak J, Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Detke HC, McDonnell DP, Lauriello J, Olanzapine long-acting injection: an 8-week double-blind, randomized, placebo-controlled study in acutely-ill patients with schizophrenia [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):152
   Google Scholar
• Lauriello J, Lambert T, Andersen S, An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790-9
   PubMed Web of Science ®Google Scholar
• EMEA. European Medicines Agency pre-authorisation evaluation of medicines for human use. Document reference: EMEA/608654/2008. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Zypadhera/H-890-en6.pdf. [Last accessed 8 March 2010]
   Google Scholar
• Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 2009;63:140-50
   Google Scholar
• Eli Lilly and Company. FDA issues not-approvable letter for Lilly's Zyprexa® long-acting injection (LAI) for schizophrenia treatment. 2008. Available from: http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=296550. [Last accessed 8 March 2010]
   Google Scholar
• Gulliver AH, McDonnell DP, Kryzhanovskaya LA, Metabolic parameters during treatment with intramuscular olanzapine. Presented at the Institute on Psychiatric Services; 2 – 5 October 2008; Chicago, IL, USA
   Google Scholar
• Detke HC, McDonnell DP, Kane JM, Olanzapine long-acting injection for the maintenance treatment of schizophrenia: a 24-week, randomized, double-blind trial [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):151-2
   Google Scholar
• Detke HC, McDonnell DP, Andersen SW, Watson SB. 160-week interim results from an open-label extension trial of olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):151
   Google Scholar
• Horne RL. Long term open label study of olanzapine pamoate: efficacy and effect on weight. 161st Annual Meeting of the American Psychiatric Association; 3 – 8 May 2008; Arlington, VA, USA
   Google Scholar
• De Hert M, Dekker JM, Wood D, Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24
   PubMed Web of Science ®Google Scholar
• Akhras KS, Singh J, Gopal S, Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres. Int J Clin Pract 2009;63:962-3
   PubMed Web of Science ®Google Scholar
• Sato Y, Yasui-Furukori N, Saito M, Comparison of metabolic factors by cookie test between schizophrenic patients during treatments with olanzapine or risperidone [abstract]. Int J Neuropsychopharmacol 2008;11(Suppl 1):153-4
   Google Scholar